Grants to improve and accelerate the diagnosis of rare and undiagnosed conditions were made to academic medical centers across the nation Monday. The new awards are part of the second phase of the National Institutes of Health’s Undiagnosed Diseases Network (UDN). The total investment planned for the UDN over the next 4 years will be approximately $100 million, pending the availability of funds.

These grants will expand the UDN from 7 to 12 clinical sites, increasing the geographical distribution of the nationwide network and the number of people with access to a UDN clinical site. Since opening to applications in 2015, the network has already diagnosed over 200 cases that had long been mysteries to the medical community.

“The UDN is pioneering a new personalized medicine model for helping those patients who have historically been the most difficult for the medical community to diagnose,” said James M. Anderson, MD, PhD, director of NIH’s Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), which provides financial support and joint leadership for the network via the NIH Common Fund. “By bringing together a nationwide network of top clinicians and laboratory researchers using the most up-to-date medical technology and knowledge, the UDN is able to provide hope to these patients, and in many cases discover a diagnosis.”

The UDN was launched to build on the success of the Undiagnosed Diseases Program (UDP) at the NIH Clinical Center. “The UDN takes advantage of cutting-edge technologies, such as genomic sequencing, metabolomics, and assessing patient variants in model organisms to give clinicians new, powerful information to help understand the cause of extremely rare diseases,” said Anastasia L. Wise, PhD, program director for the UDN in the National Human Genome Research Institute’s Division of Genomic Medicine.

Five new clinical sites will join the existing 7 academic clinical sites at Baylor College of Medicine, Houston; Duke University, Durham, North Carolina; Columbia University, New York City; Brigham and Women’s Hospital, Boston Children’s Hospital, and Massachusetts General Hospital at Harvard Medical School; Stanford Medicine, California; the University of California Los Angeles; Vanderbilt University Medical Center, Nashville, Tennessee; and the NIH UDP, Bethesda, Maryland from phase 1 to make up phase 2 of the UDN. The five new clinical sites are:

•Children’s Hospital of Philadelphia and the Hospital of University of Pennsylvania; Principal Investigators: Kathleen Sullivan, MD, PhD and Reed Pyeritz, MD, PhD.
•University of Miami School of Medicine; Principal Investigators: Mustafa Tekin, MD and Stephan Zuchner, MD, PhD.
•University of Utah, Salt Lake City; Principal Investigator: Lorenzo Botto, MD.
•University of Washington School of Medicine, Seattle, and Seattle Children’s Hospital; Principal Investigators: Gail Jarvik, MD, PhD and Katrina Dipple, MD, PhD.
•Washington University in St. Louis; Principal Investigator: Francis Sessions Cole, MD.

In addition to the new clinical sites, new research cores will be part of phase 2 of the UDN. A new Metabolomics Core at the Mayo Clinic, Rochester, Minnesota, has been awarded (Principal Investigators: Ian Lanza, PhD and Devin Oglesbee, PhD), providing untargeted metabolomics and targeted biomarker analyses, and a new Model Organisms Screening Center at Washington University in St. Louis, (Principal Investigators: Lilianna Solnica-Krezel, PhD and Tim Schedl, PhD), increasing the zebrafish modeling capacity and adding C. elegans as a new model system for the UDN.

Phase 2 of the UDN will also retain the coordinating center at Harvard Medical School and University of Alabama at Birmingham, the genome sequencing core at Baylor College of Medicine, and the model organism screening center at Baylor College of Medicine and the University of Oregon, Eugene. A complete list of funded awards can be found at https://commonfund.nih.gov/Diseases/fundedresearch.